Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 36 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Taper Plan Clear all
Terminated Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

NCT01875237
View directory record Official record
Conditions
Leukemia, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 30, 2026, 4:57 PM EDT
Recruiting Phase 1 Interventional

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

NCT07302776
View directory record Official record
Conditions
GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis (MF), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Tacrolimus, Early Tacrolimus Taper Strategy
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 4:57 PM EDT
Terminated Phase 2 Interventional Results available

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

NCT01790295
View directory record Official record
Conditions
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis
Interventions
Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Westwood, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 30, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Study to Treat Major Depressive Disorder (MDD) With a New Medication

NCT02149836
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
ezogabine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 30, 2026, 4:57 PM EDT
Recruiting Not applicable Interventional

Preoperative Opioid Tapering Before Spine Surgery

NCT07221786
View directory record Official record
Conditions
Opioid Consumption, Postoperative, Pain After Surgery, Opioid Dependency
Interventions
Opioid tapering with CBT and education, Opioid tapering with education alone
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadephia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 30, 2026, 4:57 PM EDT
Not yet recruiting Phase 3 Interventional

An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service

NCT07296770
View directory record Official record
Conditions
Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery
Interventions
TPS-Select, Pharmacologic Pain Management, Interventional Pain Procedures, Psychological Management and Pain Education, Physical Therapy
Device · Drug · Procedure + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 4:57 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Better Options for Chronic Cancer Pain

NCT06574009
View directory record Official record
Conditions
Chronic Pain, Cancer Survivor, Opioid Dependence
Interventions
Multimodal pain care, Medication optimization, Buprenorphine rotation, Opioid tapering
Behavioral · Drug · Device + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 30, 2026, 4:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

HAT for the Treatment of Sepsis Associated With NASTI

NCT05157360
View directory record Official record
Conditions
Necrotizing Soft Tissue Infection, Sepsis
Interventions
HAT, Placebo
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 30, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Results available

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

NCT03755414
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile
Procedure · Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 30, 2026, 4:57 PM EDT
Completed Not applicable Interventional

SWEET: Postpartum Navigation After GDM

NCT04583839
View directory record Official record
Conditions
Gestational Diabetes, Preventive Care / Anticipatory Guidance, Retention in Care, Postpartum Health, Lifestyle Modification
Interventions
Patient Navigation Program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 30, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

NCT00241358
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic, Myelodysplastic Syndromes, Multiple Myeloma, Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions
AMD3100, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 30, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Pediatric GVHD Low Risk Steroid Taper Trial

NCT05090384
View directory record Official record
Conditions
Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
Interventions
Prednisone
Drug
Lead sponsor
John Levine
Other
Eligibility
Up to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 30, 2026, 4:57 PM EDT